(FILE 'HOME' ENTERED AT 12:49:11 ON 23 JAN 2007)

=> s 114 and (magnesium)

L16

0 L14 AND (MAGNESIUM)

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CAPLUS, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIOBASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDLINE, NAPRALERT, NLDB, NUTRACEUT, PASCAL, ...' ENTERED AT 12:49:22 ON 23 JAN 2007 333 S 199114-18-6/RN OR 199114-17-5/RN OR 199114-04-0/RN OR 199113-L1L2270 DUP REM L1 (63 DUPLICATES REMOVED) L36 S L2 AND PD<1999 L40 S L3 AND (CELLULOSE) 0 S L3 AND (MICROCRYSTALLINE OR MICROCRYSTAL) L5L6 0 S L3 AND (STABILITY OR STABLE) 0 S L3 AND AVICEL L7 52 S MICROCRYSTALLINE (P) (ANTIDIABETIC OR THIAZOLIDINEDIONES) L8 45 DUP REM L8 (7 DUPLICATES REMOVED) L9 35 S L9 AND (MICROCRYSTALLINE (W) CELLULOSE) L10 L114 S L10 AND PD<1999 L12 1 S L11 AND (ANHYDROUS OR LACTOSE) L13 0 S L12 AND (COMPRESSION) L141 S L12 AND (ANHYDROUS OR WATER) => s 114 and (magnesium and talc) 0 L14 AND (MAGNESIUM AND TALC) L15

```
L11 ANSWER 1 OF 4 IFIPAT COPYRIGHT 2007 IFI on STN
AN
      03661677 IFIPAT; IFIUDB; IFICDB
      HIGH RELEASE SOLID PREPARATION, PREPARATION AND USE THEREOF; ORAL
TI
      ADMINISTERING
      Remon; Jean Paul, Ghent, BE
INF
      Remon Jean Paul (BE)
IN
      Rijksuniversiteit Gent Laboratorium Voor Farmaceutishe, DE
PAF
PA
      Gent, Universiteit BE (48476)
EXNAM Page, Thurman K
EXNAM Sheikh, Humera N
AG
      Sughrue Mion, PLLC
PΙ
      US 6368634
                      B1 20020409
      WO 9423700
                          19941027
      US 1996-537793
ΑI
                          19960227
      WO 1994-BE29
                          19940421
                          19960227 PCT 371 date
                          19960227 PCT 102(e) date
XPD
      9 Apr 2019
      BE 1993-407
PRAI
                          19930422
FI
      US 6368634
                          20020409
DT
      Utility
FS
      CHEMICAL
      GRANTED
MRN
      007885 MFN: 0504
CLMN
     38
       4 Drawing Sheet(s), 11 Figure(s). US 6368634 B1 20020409
GΙ
PΙ
      US 6368634
      WO 9423700
                         19941027
ACLM
               the pellet to gel in water or in gastric medium, said process
      comprising: mixing together the active agent, the solid
      microcrystalline cellulose particles and the
      solubilizer as the only solubilizer present, so as to form a liquid
      solution of the active agent.
          components which can cause the pellet to gel in water or in gastric
      medium, said process comprising: mixing together solid
      microcrystalline cellulose particles and the active
      agent in powder form, mixing the so obtained mixture with the
      solubilizer, as the only solubilizer.
          solubilizer as the only solubilizer present for forming a solution in
      which the active agent is dissolved, and (c) solid
      microcrystalline cellulose particles on which said
      solution is fixed, said particles containing said solution being
      agglomerated in an agglomerate which is not.
          in which the active agent is dissolved in the solubilizer, and (b) a
      carrier consisting of an agglomeration of solid microcrystalline
      cellulose particles, said liquid solution being fixed on or in
      the carrier, said method comprising: dissolving the active agent in said
      solubilizer as the only solubilizer present so as to form said liquid
      solution; mixing said solid microcrystalline cellulose
      particles with the liquid solution so as to form a composition of solid
     particles containing said liquid solution; agglomerating the.
      . which the active agent is selected from the group consisting of
     hydrochlorothiazide, acetazolamide, acetylsalicylic acid, allopurinol,
      alprenolol, amiloride, antiarrhythmic, antibiotic, antidiabetic
      , antiepileptic, anticoagulants, antimycotic, atenolol,
     bendroflumethiazide, benzbromarone, benzthiazide, betamethasone, ester
      thereof, bronchodilator, buphenine, bupranolol, chemotherapeutic,
      chlordiazepoxide, chloroquine, chlorothiazide, chlorpromazine,
      chlortalidone, clenbuterol,.
      38. Mixture of claim 21, in which the particles are selected from the
     group consisting of microcrystalline particles and water
```

insoluble particles.

```
L11 ANSWER 2 OF 4 IFIPAT COPYRIGHT 2007 IFI on STN
AN
      02781369 IFIPAT; IFIUDB; IFICDB
      REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS;
TI
      LOW SOLUBILITY DRUGS WITH HIGH BIOAVAILABILITY, STERIC STABILIZER
      Desieno, Mark A, Gilbertsville, PA
INF
      Stetsko, Gregg, Harleysville, PA
      Desieno Mark A; Stetsko Gregg
IN
      Nano Systems LLC, Collegeville, PA
PAF
PΑ
      NanoSystems LLC (38571)
EXNAM Page, Thurman K
EXNAM Benston, Jr, William E
AG
      Rudman & Balogh
ΡI
      US 5573783
                          19961112 (CITED IN 010 LATER PATENTS)
ΑI
      US 1995-387651
                          19950213
XPD
      13 Feb 2015
FΤ
      US 5573783
                          19961112
DT
      Utility
FS
      CHEMICAL
      GRANTED
              MFN: 0154
MRN
      007359
      007817
                    0273
      007820
                    0153
      007987
                    0025
CLMN
      28
ΡI
      US 5573783
                      A 19961112 (CITED IN 010 LATER PATENTS)
      . . . 2 wherein the drug is selected from the group consisting of
ACLM
      analgesics, anti-inflammatory agents, anthelminitics, anti-arrhythmic
      agents, antibiotics, anticoagulant, antidepressants, antidiabetic
      agents, antiepileptics, antihistamines, antihypertensive agents,
      antimuscarinic agents, antimycobacterial agents, antineoplastic agents,
      immunosuppressants, antithyroid agents, antiviral agents, anxiolytic
      sedatives, astringents, beta-adrenoceptor.
          14. The composition of claim 1 wherein the carrier particle is
      selected from the group consisting of sugar spheres, maltodextrin,
      microcrystalline cellulose, microcrystal
      cellulose/sodium carboxylmethylcellulose, granular dextrose, dicalcium
      phosphate, tricalcium phosphate, mono and disaccharides.
          17 wherein the drug is selected from the group consisting of
      analgesics, anti-inflammatory agents, anthelminitics, anti-arrhythmic
      agents, antibiotics, anticoagulant, antidepressants, antidiabetic
      agents, antiepileptics, antihistamines, antihypertensive agents,
      antimuscarinic agents, antimycobacterial agents, antineoplastic agents,
      immunosuppressants, antithyroid agents, antiviral agents, anxiolytic
      sedatives, astringents, beta-adrenoceptor.
L11 ANSWER 3 OF 4 IFIPAT COPYRIGHT 2007 IFI on STN
AN
      01988916 IFIPAT; IFIUDB; IFICDB
TI
      ORAL ANTI-DIABETIC PHARMACEUTICAL COMPOSITIONS AND THE PREPARATION
      THEREOF; ACID, BASIC OR AMPHOTERIC BENZOIC ACID DERIVATIVES WITH
      EXCIPIENTS, SOLVENTS, SOLUBILIZERS, CARRIERS
      Brickl, Rolf, Warthausen, DE
INF
      Greischel, Andreas, Biberach, DE
      Rupprecht, Eckhard, Aulendorf-Tannhausen, DE
      Schepky, Gottfried, Biberach, DE
ΙN
      BRICKL ROLF (DE); GREISCHEL ANDREAS (DE); RUPPRECHT ECKHARD (DE); SCHEPKY
      GOTTFRIED (DE)
PAF
      Dr Karl Thomae GmbH, Biberach an der Riss, DE
      THOMAE, DR KARL GMBH DE (84368)
EXNAM Rollins, John W
      Felfe & Lynch
AG
PT
      US 4873080
                          19891010 (CITED IN 004 LATER PATENTS)
```

```
ΑI
      US 1987-103524
                          19870930
XPD
      10 Oct 2006
RLI
     US 1984-616010
                          19840531 CONTINUATION-IN-PART
PRAI DE 1983-3320583
                          19830608
     US 4873080
                          19891010
FΙ
      US 4708868
DT
      Utility
      CHEMICAL
FS
      GRANTED
OS
      CA 112:223301
MRN
      005115
             MFN: 0672
CLMN
GΙ
      16 Drawing Sheet(s), 16 Figure(s).
PΙ
      US 4873080
                     A 19891010 (CITED IN 004 LATER PATENTS)
ACLM
        . . claim 1, wherein the dry treated water-insoluble carrier is
      combined with a conventional pharmaceutical excipient to produce the
      desired oral antidiabetic pharmaceutical composition.
          The method of claim 1, wherein the water-insoluble carrier is
      selected from the group consisting of highly dispersed silicon dioxide,
      microcrystalline cellulose, basic aluminum oxide,
      magnesium-aluminum-trisilicate, cross-linked polyvinylpyrrolidone, sodium
      carboxymethyl starch, tricalcium phosphate, calcium biphosphate and
      mixtures thereof, and the solubilizing or.
      9. An oral antidiabetic pharmaceutical composition consisting
      essentially of a conventional pharmaceutical excipient and a dry
      water-insoluble carrier having applied to the surface thereof the
      evaporation residue of a solution or emulsion of an effective
      antidiabetic amount of an acid, amphoteric or basic
      antidiabetic benzoic acid, a basic or acid excipient, and at
      least one solubilizing or emulsifying substance in an inert polar
      solvent,.
          is sulfuric acid or tartaric acid, the water-insoluble carrier is
      selected from the group consisting of highly dispersed silicon dioxide,
      microcrystalline cellulose, basic aluminum oxide,
      magnesium-aluminum-trisilicate, cross-linked polyvinylpyrrolidone, sodium
      carboxymethyl starch, tricalcium phosphate, calcium biphosphate and
      mixtures thereof, and the solubilitizing or.
L11 ANSWER 4 OF 4 IFIPAT COPYRIGHT 2007 IFI on STN
AN
      01812788 IFIPAT; IFIUDB; IFICDB
ΤI
      ORAL ANTI-DIABETIC PHARMACEUTICAL FORMS AND THE PREPARATION THEREOF
INF
      Brickl, Rolf, Warthausen, DE
      Greischel, Andreas, Biberach, DE
      Rupprecht, Eckhard, Aulendorf-Tannhausen, DE
      Schepky, Gottfried, Biberach, DE
ΙN
      BRICKL ROLF (DE); GREISCHEL ANDREAS (DE); RUPPRECHT ECKHARD (DE); SCHEPKY
      GOTTFRIED (DE)
      Dr Karl Thomae GmbH, Biberach an der Riss, DE
PAF
      THOMAE, DR KARL GMBH DE (84368)
EXNAM Brown, J R
EXNAM Rollins, John W
     Weissenberger, Hammond & Littell
AG
      US 4708868
PΙ
                     A 19871124 (CITED IN 019 LATER PATENTS)
ΑI
     US 1984-616010
                          19840531
XPD
      24 Nov 2004
PRAI DE 1983-3320583
                          19830608
FT
     US 4708868
                          19871124
DT
     Utility
FS .
     CHEMICAL
     GRANTED
MRN
      004760
              MFN: 0524
CLMN 16
       10 Drawing Sheet(s), 10 Figure(s).
```

A 19871124 (CITED IN 019 LATER PATENTS)

ACLM . . . The method of claim 1, wherein the water-insoluble carrier is selected from the group consisting of highly dispersed silicon dioxide, microcrystalline cellulose, basic aluminum oxide, magnesium-aluminum-trisilicate, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, tricalcium phosphate, calcium biphosphate and mixtures thereof, and the solubilizing or.

. claim 1, wherein the dry treated water-insoluble carrier is combined with a conventional pharmaceutical excipient to produce the desired oral antidiabetic pharmaceutical composition.

10. An oral antidiabetic pharmaceutical composition consisting essentially of a conventional pharmaceutical excipient and a dry water-insoluble carrier having applied to the surface thereof the evaporation residue of a solution or emulsion of an effective antidiabetic amount of an acid, amphoteric or basic antidiabetic sulfonyl urea, a basic or acid excipient, and at least one solubilizing or emulsifying substance in an inert polar

. the acid excipient is sulfuric acid, the water-insoluble carrier is selected from the group consisting of highly dispersed silicon dioxide, microcrystalline cellulose, basic aluminum oxide, magnesium-aluminum-trisilicate, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, tricalcium phosphate, calcium biphosphate and mixtures thereof, and the solubilizing or. . .